These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32462838)

  • 1. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy].
    Mechahougui H; Achard V; Friedlaender A
    Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.
    Brungs D; Chen J; Masson P; Epstein RJ
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):105-11. PubMed ID: 24686773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
    Ghamande SS; Klaassen Z; Wallis CJD
    Eur Urol; 2023 Sep; 84(3):350-351. PubMed ID: 37183160
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
    Pinto Á
    Cancer Biol Ther; 2014 Feb; 15(2):149-55. PubMed ID: 24100689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
    Swami U; Hong A; El-Chaar NN; Ramaswamy K; Diessner BJ; Blauer-Peterson CJ; Sandin R; Nimke D; Agarwal N
    J Urol; 2023 Jun; 209(6):1120-1131. PubMed ID: 36789668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Hormones and Prostate Cancer.
    Auchus RJ; Sharifi N
    Annu Rev Med; 2020 Jan; 71():33-45. PubMed ID: 31613683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
    Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
    Expert Rev Anticancer Ther; 2021 Apr; 21(4):389-400. PubMed ID: 33245666
    [No Abstract]   [Full Text] [Related]  

  • 11. Progress in the treatment of advanced prostate cancer.
    Sternberg CN; Petrylak DP; Madan RA; Parker C
    Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.
    Alva A; Hussain M
    Drugs; 2013 Sep; 73(14):1517-24. PubMed ID: 23959841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
    Hoeh B; Chun FKH; Mandel P
    Chin Clin Oncol; 2024 Feb; 13(1):14. PubMed ID: 37817509
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.